CommercialCoverageMedium impact
08.01.23j, Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur)
Independence Blue Cross·Pulmonology, Allergy & Immunology, Internal Medicine·Medical Policy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
Updates to medical necessity criteria, coding guidelines, and general information for Interleukin-5 (IL-5) Antagonist medications like Cinqair and Exdensur. This policy affects commercial insurance coverage for these specialized asthma and eosinophilic disorder treatments.
Action Required
Before March 23, 2026: Billing team must review updated medical necessity criteria for IL-5 antagonist medications (Cinqair, Exdensur). Update prior authorization workflows and ensure documentation requirements align with new policy guidelines. Providers treating severe asthma or eosinophilic disorders should review coverage criteria to ensure appropriate patient selection and documentation.